EP0301900A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
L'utilisation de riboside ou ribotide de l'AICA pour la fabrication d'un médicament contre la crise cardiaque ou l'infarctus du myocarde aux patients souffrant d'athérosclerosis.
Assignee: University of California
•
Filing: 1988-07-29
•
Granted: —
•
Expires: 2008-07-29
Abstract
Abstract Methods for increasing extracellular concentrations of adenosine for the prophylactic or affirmative treatment of diseases of the immune, nervous, cardiac, and vascular systems involving administering to a patient purine nucleoside and purine nucleoside-related analogs which increase extracellular adenosine concentrations, and methods for stabilizing mast cells by the suppression of mast cell activation using such compounds.
Inventors
- 👤 Harry Edward Gruber
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 08:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7042; A61K31/7052; A61K31/7056; A61K38/00; A61K38/16; A61K38/164; A61K38/166; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61P; A61P9/00; C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/052; C07H19/056
Claims Analysis
Total Claims: 42
Claim 1
Independent Claim
67 words
The use of a purine nucleoside compound or analogue which selectively enhances the extracellular concentrations of adenosine in a tissue for the manufacture of a medicament for the prophylactic or affirmative treatment of a pathologic or allergic condition; or for enhancing the extracellular concentration of adenosine surrounding cells undergoing an undesired increased cellular excitation; or decreasing or preventing mast cell activation or production of leukotrienes or both.
Claim 2
Dependent Claim
67 words
The use of a purine nucleoside compound or analogue which selectively enhances the extracellular concentrations of adenosine in a tissue for the manufacture of a medicament for the prophylactic or affirmative treatment of a pathologic or allergic condition; or for enhancing the extracellular concentration of adenosine surrounding cells undergoing an undesired increased cellular excitation; or decreasing or preventing mast cell activation or production of leukotrienes or both.
Claim 3
Dependent Claim
22 words
The use according to claim 1 where the tissue is kidney, bowel, skeletal muscle, skin-tissue or retinal tissue or peripheral nerve tissue.
Claim 4
Dependent Claim
18 words
The use according to claim 2 where the tissue is kidney, bowel, skeletal muscle, skin-tissue or retinal microvasculature.
Claim 5
Dependent Claim
33 words
The use according to any one of claims 1 to 3 wherein the dosage amount of the purine nucleotide compound or analogue used in the treatment is from 0.1 mg/kg/day to 500 mg/kg/day.
Claim 6
Dependent Claim
23 words
The use according to any one of claims 1 to 4 wherein the purine nucleoside compound or analogue is AICA riboside or ribavirin.
Claim 7
Dependent Claim
76 words
The use according to any one of claims 1 to 5 wherein the pathologic condition is diabetes mellitus, stroke, migraine headache, Raynaud's phenomenon, myocardial arrythmia, atherosclerosis, vascular thrombosis, vascular spasm; or the allergic condition is hay fever, asthma, eczema, chronic urticari, urticari pigmentosa, allergic conjunctivitis or allergic rhinitis; or the increased cellular excitation results in a seizure or epilepsy, arrhythmia or arrhythmias, arthritis, autoimmune disease, inflammation, or Adult Respiratory Distress Syndrome or occurs during adrenergic therapy.
Claim 8
Dependent Claim
34 words
The use of an adenosine monophosphate deaminase inhibitor for the manufacture of a medicament for use in selectively enhancing the extracellular concentration of adenosine in tissue having an undesired region of decreased blood flow.
Claim 9
Dependent Claim
34 words
The use of an adenosine monophosphate deaminase inhibitor for the manufacture of a medicament for use in selectively enhancing the extracellular concentration of adenosine in tissue having an undesired region of decreased blood flow.
Claim 10
Dependent Claim
23 words
The use according to claim 7 wherein the adenosine monophosphate deaminase inhibitor is selected from AICA riboside, AICA ribotide, ribavirin and ribavirin monophosphate.
Claim 11
Dependent Claim
52 words
The use of a purine nucleoside compound or analogue which enhances the cellular synthesis and release of adenosine for the manufacture of a medicament for enhancing the extracellular concentration of adenosine around cells having a decreased ratio of synthesis of adenosine triphosphate to breakdown of adenosine triphosphate due to a pathologic process.
Claim 12
Dependent Claim
52 words
The use of a purine nucleoside compound or analogue which enhances the cellular synthesis and release of adenosine for the manufacture of a medicament for enhancing the extracellular concentration of adenosine around cells having a decreased ratio of synthesis of adenosine triphosphate to breakdown of adenosine triphosphate due to a pathologic process.
Claim 13
Dependent Claim
24 words
The use according to claim 9 wherein the purine nucleoside compound or analogue is selected from AICA riboside, AICA ribotide, ribavirin, and ribavirin monophosphate.
Claim 14
Dependent Claim
23 words
The use according to claim 9 or claim 10 wherein the pathologic process is a seizure, arthritis, Adult Respiratory Distress Syndrome or inflammation.
Claim 15
Dependent Claim
20 words
The use according to claim 11 wherein the pathologic process is inflammation which causes or is believed to cause atherosclerosis.
Claim 16
Dependent Claim
22 words
The use according to claim 11 or 12 wherein the pathologic process is inflammation due to granulocyte activation or mononuclear cell activation.
Claim 17
Dependent Claim
30 words
The use according to claim 13 wherein the inflammation due to granulocyte activation relates to blood exposure to heart-lung or dialysis machines, or to other artificial membranes or is psoriasis.
Claim 18
Dependent Claim
19 words
The use according to claim 13 wherein said inflammation due to mononuclear cell activation relates to organ transplant rejection.
Claim 19
Dependent Claim
35 words
The use according to claim 9 or claim 10 wherein the pathologic process is a stroke, a transient ischemic attack, a heart attack, angina pectoris, intermittent claudication of skeletal muscle, bowel ischemia or kidney ischemia.
Claim 20
Dependent Claim
45 words
The use of a purine nucleoside compound or analogue which enhances the cellular synthesis and release of adenosine for the manufacture of a medicament for use in treating patients having chronic low adenosine levels or who would benefit from increased central nervous system adenosine levels.
Claim 21
Dependent Claim
45 words
The use of a purine nucleoside compound or analogue which enhances the cellular synthesis and release of adenosine for the manufacture of a medicament for use in treating patients having chronic low adenosine levels or who would benefit from increased central nervous system adenosine levels.
Claim 22
Dependent Claim
21 words
The use according to claim 17 wherein the patients have or are believed to have autism, cerebral palsy, insomnia or schizophrenia.
Claim 23
Dependent Claim
26 words
The use of a drug selected from AICA riboside, AICA ribotide, ribavirin, and ribavirin monophosphate for the manufacture of a medicament for the treatment of autism.
Claim 24
Dependent Claim
26 words
The use of a drug selected from AICA riboside, AICA ribotide, ribavirin, and ribavirin monophosphate for the manufacture of a medicament for the treatment of autism.
Claim 25
Dependent Claim
24 words
The use according to any one of claims 1 to 19 wherein the drug further comprises a pharmaceutically acceptable amount of a thrombolytic agent.
Claim 26
Dependent Claim
21 words
The use according to claim 20, wherein the thrombolytic agent is selected from tissue plasminogen activator, streptokinase, urokinase, heparin, and coumadin.
Claim 27
Dependent Claim
38 words
The use of AICA ribotide according to any one of claims 1 to 21 wherein the medicament further comprises a pharmaceutically acceptable amount of an agent to enhance the amount of endogenous AICA ribotide or prevent its metabolism.
Claim 28
Dependent Claim
23 words
The use according to claim 22 wherein the agent is selected from succinylaminoimidazole carboxamide riboside, succinylaminoimidazole carboxamide ribotide, methotrexate, ribavirin and sulfonamide drugs.
Claim 29
Dependent Claim
19 words
The use according to claim 7 wherein the adrenergic therapy comprises the administration of catecholamines or functional catecholamine analogues.
Claim 30
Dependent Claim
17 words
The use according to any one of claims 1 to 24 wherein the medicament further comprises allopurinol.
Claim 31
Dependent Claim
23 words
The use according to any one of claims 1 to 25 wherein the treatment comprises administration of at least 50 mg/day of allopurinol.
Claim 32
Dependent Claim
27 words
The use according to any one of claims 1 to 26 wherein the treatment comprises intravenous, oral intramuscular, topical or rectal administration or inhalation of the medicament.
Claim 33
Dependent Claim
31 words
A formulation comprising a pharmaceutically acceptable carrier and at least 1 mg of a compound selected from AICA riboside, AICA ribotide, and ribavirin monophosphate for treatment of humans and other animals.
Claim 34
Dependent Claim
31 words
A formulation comprising a pharmaceutically acceptable carrier and at least 1 mg of a compound selected from AICA riboside, AICA ribotide, and ribavirin monophosphate for treatment of humans and other animals.
Claim 35
Dependent Claim
19 words
A composition according to claim 28 wherein the compound is present in an amount of at least 50 mg.
Claim 36
Dependent Claim
19 words
A composition according to claim 29 wherein the compound is present in an amount of at least 100 mg.
Claim 37
Dependent Claim
19 words
A composition according to claim 30 wherein the compound is present in an amount of at least 500 mg.
Claim 38
Independent Claim
71 words
A method of screening purine nucleoside compunds or analogues for the ability to enhance the cellular synthesis and release of adenosine comprising: administering to the cultured cells a first composition comprising the purine nucleoside compound or analogue to be screened; administering to the cultured cells a second composition comprising a compound which promotes net catabolism of adenosine triphosphate; and determining the level or amount of adenosine released by the cultured cells.
Claim 39
Independent Claim
71 words
A method of screening purine nucleoside compunds or analogues for the ability to enhance the cellular synthesis and release of adenosine comprising: administering to the cultured cells a first composition comprising the purine nucleoside compound or analogue to be screened; administering to the cultured cells a second composition comprising a compound which promotes net catabolism of adenosine triphosphate; and determining the level or amount of adenosine released by the cultured cells.
Claim 40
Dependent Claim
57 words
A method according to claim 32 further comprising a first control set of the cultured cells to which neither the first composition nor the second composition is added, a second control set of cultured cells to which the first composition is added, and a third control set of cultured cells to which the second composition is added.
Claim 41
Dependent Claim
32 words
A method according to claim 31 or claim 32 wherein the cultured cells are derived from a human malignant cell line, Epstein-Barr virus transformed B lymphocytes or W1-L2 human splenic lymphoblast cells.
Claim 42
Independent Claim
27 words
A method according to any one of claims 32 to 34 wherein the compound which promotes net catabolism of adenosine triphosphate is a calcium ionophore or 2-deoxyglucose.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.